DIGITAL EDITIONS

Tag: Ingenol mebutate

Letter to the Editor: Ingenol Mebutate Induced Severe, Febrile Pustular Eruption of the Face

December 1, 2019

Dear Editor: Topical field-directed treatment is well-established for actinic keratosis (AK) lesions, which are considered premalignant sun-related skin lesions. The most commonly used local treatments for AK lesions are diclofenac, 5-fluroouracil, imiquimod, and ingenol mebutate.1 Ingenol mebutate, the latest introduction to the dermatologist’s therapeutic quiver for actinic keratosis, is an effective and well-tolerated option, with

Noninvasive Long-term Monitoring of Actinic Keratosis and Field Cancerization Following Treatment with Ingenol Mebutate Gel 0.015%

October 1, 2017

by Orit Markowitz, MD; Katie Wang, DO; Amanda Levine, MD; Michelle Schwartz, BA; Sumeet Minhas, BA; Eleanor Feldman, BA; and Daniel M. Siegel, MD Drs. Markowitz, Wang, Levine; Ms. Minhas; and Ms. Schwartz and Ms. Feldman are associated with the Department of Dermatology, SUNY Downstate Medical Center, New York, New York; the Department of Dermatology,

A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest

August 1, 2017

by Douglas C. Wu, MD, PhD; Isabella Guiha, BSc; and Mitchel P. Goldman, MD Drs. Wu and Goldman and Ms. Guiha are with Cosmetic Laser Dermatology, San Diego, California. J Clin Aesthet Dermatol. 2017;10(8):31–36 Funding: This study was sponsored and funded by LEO Pharma. Disclosures: The authors have no conflicts of interest relevant to the